Financings of the Fortnight: Getting Comfortable In Genes
This article was originally published in The Pink Sheet Daily
Executive Summary
Investor confidence in the potential for gene therapy is renewing, witness recent VC backing of GenSight and Audentes and bluebird bio’s IPO. Plus news on financings by Edimer, aTyr Pharma, Dicerna, and BioMotiv.